Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.55 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900153 | 0.84 | GLRA1 (0.52) | GLRA1MRGPRX4MAOBSMN1; SMN2TP53 | |
| SCHEMBL4898911 | 0.84 | GLRA1 (0.58) | GLRA1MRGPRX4PTPRCPTPN1MAOB | |
| SCHEMBL4894163 | 0.84 | MRGPRX4 (0.59) | MRGPRX4PTPRCPTPN1MAOBSMN1; SMN2 | |
| SCHEMBL4896413 | 0.83 | MRGPRX4 (0.57) | MRGPRX4PTPRCPTPN1MAOBSMN1; SMN2 | |
| SCHEMBL4888400 | 0.77 | GLRA1 (0.54) | GLRA1MRGPRX4PTPRCPTPN1FFAR1 | |
| SCHEMBL16860678 | 0.75 | GLRA1 (0.79) | GLRA1MRGPRX4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27955353 | 0.74 | MRGPRX4 (0.65) | MRGPRX4MAOBSMN1; SMN2TP53PKM | |
| SCHEMBL16860746 | 0.73 | GLRA1 (1.00) | GLRA1MRGPRX4MAOBSMN1; SMN2MEN1 | |
| SCHEMBL6274294 | 0.73 | MRGPRX4 (0.48) | MRGPRX4MAOBSMN1; SMN2TP53PKM | |
| SCHEMBL2682408 | 0.73 | CES2 (0.81) | MAOBSMN1; SMN2MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | GLRA1 926/4885MRGPRX4 344/4885PTPRC 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.